前列腺癌分子影像标准化评价框架第二版(PROMISE V2),纳入临床试验疗效评估
PROMISE V2 是前列腺癌 PSMA-PET 影像解读与报告的综合框架,整合更新的 miTNM 分期系统、改进的局部病灶评估和略作修改的 PSMA 表达评分,并新增用于临床试验纵向评估的疗效监测框架,定义需记录的定性与定量参数。
要点
- PROMISE V2 整合更新版 miTNM 系统、改进的局部病灶评估及略作修改的 PSMA 表达评分。
- 新增疗效监测框架,定义临床试验纵向评估需记录的定性与定量参数。
- PSMA 表达评分低是 177Lu-PSMA 放射配体治疗后总生存的负性预后因素。
核心结论
- PROMISE V2 为临床常规与研究提供疾病范围的标准化报告,试验内记录的参数有助于客观疗效评估。
研究设计与样本
- 本文提出 PROMISE V2 框架,并附关于 PROMISE 框架在临床研究与前瞻性试验中应用情况的综合文献综述。
主要发现
- PROMISE 变量显示与生存有明确关联。
- 多个试验采用 PSMA 表达评分评估 PSMA 表达,PSMA 表达评分低是 177Lu-PSMA 放射配体治疗后总生存的负性预后因素。
- 试验中拟记录的影像参数可用于按 PSMA-PET 进展(PPP)或 PSMA-PET/CT 疗效评价标准(RECIP)框架判定疗效,也可用于未来疗效标准。
关键数值与推荐
- PROMISE V2 整合更新的 miTNM 系统、改进的局部疾病评估和略作修改的 PSMA 表达评分用于临床常规。
- 新增疗效监测框架,定义临床试验纵向评估需记录的定性与定量参数。
临床怎么用
- PROMISE V2 为临床常规与研究提供疾病范围的标准化报告,试验内记录的参数有助于客观疗效评估。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Prostate-specific membrane antigen (PSMA) targeting positron emission tomography (PET) is emerging to become a reference imaging tool for the staging and restaging of patients with prostate cancer for both clinical routine and trials. The prostate cancer molecular imaging standardized evaluation (PROMISE) criteria have been proposed as a framework for whole-body staging (molecular imaging TNM staging, denoted miTNM staging) to describe the prostate cancer disease extent on PSMA-PET. OBJECTIVE: To create a comprehensive and integrated framework for PSMA-PET image interpretation and reporting. EVIDENCE ACQUISITION: We propose the PROMISE V2 framework, which integrates an updated miTNM system, improved assessment of local disease, and a slightly modified PSMA-expression score for clinical routine. We have added a response monitoring framework defining qualitative and quantitative parameters to be recorded for a longitudinal assessment in clinical trials. EVIDENCE SYNTHESIS: We provide a comprehensive literature review on the current use of the PROMISE framework in clinical research and prospective trials. PROMISE variables demonstrate a clear association with survival. PSMA expression assessed by the PSMA-expression score was used in several trials, and a low PSMA-expression score is a negative prognosticator of overall survival after 177Lu-PSMA radioligand therapy. The proposed imaging parameters recorded for response assessment in clinical trials can be utilized to determine response according to PSMA-PET progression (PPP) or Response Evaluation Criteria in PSMA-PET/Computed Tomography (RECIP) frameworks, but also future response criteria. CONCLUSIONS: PROMISE V2 offers standardized reporting of disease extent for clinical routine and research. Parameters recorded within clinical trials facilitate objective response assessment. PATIENT SUMMARY: Prostate-specific membrane antigen (PSMA) targeting positron emission tomography (PET) has become a standard imaging examination for prostate cancer. We propose a comprehensive framework for the analysis and reporting of PSMA-PET findings that will improve the communication between imaging experts and uro-oncologists.
引用
- Seifert R, Emmett L, Rowe SP, et al. Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2). Eur Urol. 2023. PMID: 36935345. doi:10.1016/j.eururo.2023.02.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。